Advertisement
UK markets open in 6 hours 15 minutes

  • NIKKEI 225

    37,590.92
    -37.56 (-0.10%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • CRUDE OIL

    83.90
    +0.33 (+0.39%)
     

  • GOLD FUTURES

    2,341.20
    -1.30 (-0.06%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • Bitcoin GBP

    51,318.82
    -418.06 (-0.81%)
     

  • CMC Crypto 200

    1,389.34
    +6.77 (+0.49%)
     

  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     

  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

BUZZ-Meda falls as Mylan, Abbott talks seen as bitter pill

Reuters - UK Focus

** Shares (Frankfurt: DI6.F - news) in Swedish drug maker Meda (Other OTC: MDABF - news) fall by more than 5 percent after reported deal negotiations between Mylan (NasdaqGS: MYL - news) and Abbott Laboratories (Xetra: 850103 - news) quash hopes that Mylan will return with an improved bid to buy Meda.

** A Reuters report says that Mylan is in advanced talks to buy a large part of Abbott's Europe-based mature drugs for several billion dollars, with some of the people saying the deal would allow Mylan to move its tax address overseas.

** Meda shares are down 5.6 percent at 107.70 Swedish crowns at 0937 GMT, the worst performer on the STOXX 600 Europe healthcare index.

** Mylan earlier this year sought to buy Meda, but was rejected twice by Meda's board of directors who said Meda's biggest shareholder did not support a deal.

Reuters messaging rm://sven.nordenstam.reuters.com@reuters.net